The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Evolutionary dynamics of cancer in response to targeted combination therapy
Open accessAbstract
In solid tumors, targeted treatments can lead to dramatic regressions, but responses are often short-lived because resistant cancer cells arise. The major strategy proposed for overcoming resistance is combination therapy. We present a mathematical model describing the evolutionary dynamics of lesions in response to treatment. We first studied 20 melanoma patients receiving vemurafenib. We then applied our model to an independent set of pancreatic, colorectal, and melanoma cancer patients with metastatic disease. We find that dual therapy results in long-term disease control for most patients, if there are no single mutations that cause cross-resistance to both drugs; in patients with large disease burden, triple therapy is needed. We also find that simultaneous therapy with two drugs is much more effective than sequential therapy. Our results provide realistic expectations for the efficacy of new drug combinations and inform the design of trials for new cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Exact stochastic simulation of coupled chemical reactions
Gillespie, D. T. (1977) · The Journal of Physical Chemistry · doi:10.1021/j100540a008 · Cited by 10,136
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 2×
“Similar mathematical modeling has successfully predicted the dynamics of acquired resistance, including the timing of treatment failure, in colorectal cancer patients treated with the EGFR inhibitor panitumumab (Diaz et al., 2012), and has led to specific recommendations for combination therapies…”
InfluentialSelf-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Self-citationAthreya, K. B., & Ney, P. E. (1972) · Springer eBooks · doi:10.1007/978-3-642-65371-1 · Cited by 1,665
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution
Shackleton, M., Quintana, E., Fearon, E. R., & Morrison, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.08.017 · Cited by 1,162
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 2×
“Similar mathematical modeling has successfully predicted the dynamics of acquired resistance, including the timing of treatment failure, in colorectal cancer patients treated with the EGFR inhibitor panitumumab (Diaz et al., 2012), and has led to specific recommendations for combination therapies…”
InfluentialWhole-genome analysis informs breast cancer response to aromatase inhibition
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., Van Tine, B. A., Hoog, J., Goiffon, R. J., Goldstein, T. C., et al. (2012) · Nature · doi:10.1038/nature11143 · Cited by 1,023
Cancer stem cells: mirage or reality?
Gupta, P. B., Chaffer, C. L., & Weinberg, R. A. (2009) · Nature Medicine · doi:10.1038/nm0909-1010 · Cited by 979
Dynamics of chronic myeloid leukaemia
Michor, F., Hughes, T. P., Iwasa, Y., Branford, S., Shah, N. P., Sawyers, C. L., & Nowak, M. A. (2005) · Nature · doi:10.1038/nature03669 · Cited by 833
Self-citationSequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Drug resistance in cancer: Principles of emergence and prevention
Komarova, N. L., & Wodarz, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501870102 · Cited by 414
Eskelin, S. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00182-2 · Cited by 403
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396 · cited 1×
“…targeted cancer treatment is crucial for progress in this area and has been the focus of experimental (Engelman et al., 2007; Corcoran et al., 2010; Bivona et al., 2011; Diaz et al., 2012; Ellis et al., 2012; Misale et al., 2012; Straussman et al., 2012; Wilson et al., 2012; Khorashad et al.,…”
BackgroundDeterminants of survival following HIV-1 seroconversion after the introduction of HAART
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14570-9 · Cited by 369
(1972) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/49.1.119 · Cited by 351
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
On the growth rates of human malignant tumors: Implications for medical decision making
Friberg, S., & Mattson, S. (1997) · Journal of Surgical Oncology · doi:10.1002/(sici)1096-9098(199708)65:4<284::aid-jso11>3.0.co;2-2 · Cited by 346
Evolution of Resistance During Clonal Expansion
Iwasa, Y., Nowak, M. A., & Michor, F. (2006) · Genetics · doi:10.1534/genetics.105.049791 · Cited by 233
Self-citationKhorashad, J. S., Kelley, T. W., Szankasi, P., Mason, C. C., Soverini, S., Adrian, L. T., Eide, C. A., Zabriskie, M. S., Lange, T., Estrada, J. C., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431379 · Cited by 222
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
Gerber, D. E., & Minna, J. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.033 · Cited by 220
A model for the resistance of tumor cells to cancer chemotherapeutic agents
Coldman, A. J., & Goldie, J. H. (1983) · Mathematical Biosciences · doi:10.1016/0025-5564(83)90066-4 · Cited by 154
Cell production rates in human tissues and tumours and their significance. Part II: clinical data
Rew, D. A., & Wilson, G. D. (2000) · European Journal of Surgical Oncology · doi:10.1053/ejso.1999.0907 · Cited by 131
Stochastic modeling of drug resistance in cancer
Komarova, N. L. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.08.003 · Cited by 120
Role of symmetric and asymmetric division of stem cells in developing drug resistance
Tomasetti, C., & Levy, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007726107 · Cited by 116
Evolution of Resistance to Cancer Therapy
Michor, F., Nowak, M. A., & Iwasa, Y. (2005) · Current Pharmaceutical Design · doi:10.2174/138161206775201956 · Cited by 109
Self-citationBeckman, R. A., Schemmann, G. S., & Yeang, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203559109 · Cited by 106
The dynamics of drug resistance: A mathematical perspective
Lavi, O., Gottesman, M. M., & Levy, D. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.003 · Cited by 102
Exact solution of a two-type branching process: models of tumor progression
Tibor Antal, A., & Krapivsky, P. L. (2011) · Journal of Statistical Mechanics Theory and Experiment · doi:10.1088/1742-5468/2011/08/p08018 · Cited by 88
Dynamics of targeted cancer therapy
Božić, I., Allen, B., & Nowak, M. A. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.04.006 · Cited by 86
Self-citationThe Evolution of Two Mutations During Clonal Expansion
Haeno, H., Iwasa, Y., & Michor, F. (2007) · Genetics · doi:10.1534/genetics.107.078915 · Cited by 75
Clinical opportunities and challenges in targeting tumour dormancy
Hensel, J. A., Flaig, T. W., & Theodorescu, D. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.207 · Cited by 72
A generalized Luria–Delbrück model
Dewanji, A., Luebeck, E. G., & Moolgavkar, S. H. (2005) · Mathematical Biosciences · doi:10.1016/j.mbs.2005.07.003 · Cited by 64
Lenaerts, T., Pacheco, J. M., Traulsen, A., & Dingli, D. (2009) · Haematologica · doi:10.3324/haematol.2009.015271 · Cited by 63
Komarova, N. L., Katouli, A. A., & Wodarz, D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004423 · Cited by 53
Chronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse
Dingli, D., Traulsen, A., & Pacheco, J. M. (2008) · Clinical Leukemia · doi:10.3816/clk.2008.n.017 · Cited by 33
The Worst Drug Rule Revisited: Mathematical Modeling of Cyclic Cancer Treatments
Katouli, A. A., & Komarova, N. L. (2010) · Bulletin of Mathematical Biology · doi:10.1007/s11538-010-9539-y · Cited by 32
Optimizing Combination Therapies with Existing and Future CML Drugs
Katouli, A. A., & Komarova, N. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012300 · Cited by 25
Mathematical modeling of cyclic treatments of chronic myeloid leukemia
Komarova, N. L., & Komarova, N. L. (2011) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2011.8.289 · Cited by 19
Cited by
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
“Combination therapy approaches that act through distinct pathways may help circumvent this problem (Bozic et al., 2013).”
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Self-citationHsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Non-coding RNA networks in cancer
Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.99 · Cited by 1,884
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Self-citation
Metadata
- Authors
- Bozic, I., Reiter, J. G., Allen, B., Antal, T., Chatterjee, K., Shah, P., Moon, Y. S., Yaqubie, A., Kelly, N., Le, D. T., Lipson, E. J., Chapman, P. B., Diaz, L. A., Vogelstein, B., & Nowak, M. A.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2013-06-25
- Volume
- 2
- Pages
- e00747-e00747
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W2123431502
- Cited by
- 617
- References
- 50
- FWCI
- 60.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.